מכירות החברה seastarmedical.com (ICU)

SeaStar Medical Holding (ICU) is developing breakthrough SCD systems to combat hyperinflammation in pediatric renal failure. The company aims to scale the deployment of these devices across US hospitals. The company's annual sales volume confirms demand trends, where the value 0.00 represents the current figure. However, expansion is limited by rigorous FDA trials and the complexity of integrating the method into intensive care protocols.
פילוחי מדדים מקיפים ואנליטיקה עבור SeaStar Medical Holding Corp. (ICU)

SeaStar Medical Holding monetizes its cytokine filtration ecosystem through the regular sale of disposable cartridges to clinics. This indicator quantifies the intensity of this lock-in effect, capturing the actual cash flow from product sales. The metric separates the long-term fundamental trend from random fluctuations, revealing the true stage of business maturity. By analyzing the company's commercial revenue, an investor can promptly recognize growth stagnation and avoid freezing capital.